IN2012DN03928A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03928A
IN2012DN03928A IN3928DEN2012A IN2012DN03928A IN 2012DN03928 A IN2012DN03928 A IN 2012DN03928A IN 3928DEN2012 A IN3928DEN2012 A IN 3928DEN2012A IN 2012DN03928 A IN2012DN03928 A IN 2012DN03928A
Authority
IN
India
Prior art keywords
fmdv
vaccine
methods
well
substypes
Prior art date
Application number
Inventor
David B Weiner
Bernadette Ferraro
Jian Yan
Patricia A Brown
Rodney A Bowling
Douglas R Kern
Mathura P Ramanathan
Niranjan Y Sardesai
Karuppiah Muthumani
Original Assignee
Univ Pennsylvania
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of IN2012DN03928A publication Critical patent/IN2012DN03928A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G01N2333/09—Foot-and-mouth disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV substypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
IN3928DEN2012 2009-11-02 2010-11-02 IN2012DN03928A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25746109P 2009-11-02 2009-11-02
US25745009P 2009-11-02 2009-11-02
PCT/US2010/055187 WO2011054011A2 (en) 2009-11-02 2010-11-02 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom

Publications (1)

Publication Number Publication Date
IN2012DN03928A true IN2012DN03928A (en) 2015-09-04

Family

ID=43923082

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3928DEN2012 IN2012DN03928A (en) 2009-11-02 2010-11-02

Country Status (11)

Country Link
US (4) US9109014B2 (en)
EP (1) EP2498814B1 (en)
JP (6) JP2013509203A (en)
KR (5) KR101851699B1 (en)
CN (2) CN102712931A (en)
AU (1) AU2010313132B2 (en)
BR (1) BR112012010357B1 (en)
CA (3) CA2777705C (en)
IN (1) IN2012DN03928A (en)
MX (1) MX2012004967A (en)
WO (1) WO2011054011A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260750B (en) * 2011-07-20 2013-06-05 东莞出入境检验检疫局检验检疫综合技术中心 Primers and method for real-time fluorescent reverse transcription-polymerase chain reaction (RT-PCR) detection of foot and mouth disease virus
JP2013050356A (en) * 2011-08-30 2013-03-14 National Agriculture & Food Research Organization Method for detecting foot-and-mouth disease virus using antibody
CN102702349B (en) * 2012-05-15 2013-11-20 中国农业科学院兰州兽医研究所 Bactrian camel VHH (variable domain of the heavy chain of HACbs) heavy-chain antibody for resisting foot-and-mouth disease AsiaI type viruses, preparation method and use thereof
US10058078B2 (en) 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
CN104837860A (en) * 2012-09-07 2015-08-12 新加坡科技研究局 Peptides and their uses
KR101535555B1 (en) * 2012-12-24 2015-07-10 대한민국 Recombinant foot and mouth disease viruses using the vaccine strain, O manisa strain for protection of ME-SA topotype of O serotyp
RU2522868C1 (en) * 2013-03-06 2014-07-20 Федеральное государственное унитарное предприятие "Щелковский биокомбинат" Method of production of vaccine against foot-and-mouth disease
US9993545B2 (en) * 2013-03-15 2018-06-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
WO2014154655A1 (en) * 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
CN103554234B (en) * 2013-09-05 2016-01-27 广西壮族自治区动物疫病预防控制中心 Based on the competitive ELISA method of foot and mouth disease A type VP1 albumen and monoclonal antibody thereof
CN105624124B (en) * 2014-11-07 2020-09-29 普莱柯生物工程股份有限公司 Vaccine composition for resisting O-type foot-and-mouth disease and preparation method and application thereof
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
BR112018070634A2 (en) * 2016-04-11 2019-02-05 Biogenesis Bago Hong Kong Ltd universal vaccine for viral diseases
CN105861755B (en) * 2016-06-07 2019-03-29 中国农业科学院兰州兽医研究所 For quickly detect the specific primer group of South Africa type foot and mouth disease virus and include the primer sets kit
US10172933B2 (en) * 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus
US20190275138A1 (en) * 2016-11-22 2019-09-12 The Wistar Institute Of Anatomy And Biology Foot and mouth disease virus serotype o (fmdv-o) vaccine
CN111050795B (en) * 2017-07-03 2023-09-22 巴拉特生物技术国际有限公司 Vaccine compositions based on synthetic polypeptide epitopes
KR102165358B1 (en) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 Vaccine composition for foot and mouth disease virus a serotype
JPWO2020067027A1 (en) * 2018-09-28 2021-08-30 一般財団法人阪大微生物病研究会 Construction of VLP-expressing CHO cell lines
KR102285977B1 (en) * 2019-03-15 2021-08-05 대한민국 An adjuvant which can be administered in combination with an oil emulsion for immunization of foot-and-mouth disease vaccine and vaccine composition containing the same adjuvant
KR20210002050A (en) * 2019-06-28 2021-01-06 (주)플럼라인생명과학 Vaccine composition for foot and mouth disease virus
CN113897392A (en) * 2020-07-06 2022-01-07 嘉兴安宇生物科技有限公司 Trivalent recombinant adenovirus vaccine for foot-and-mouth disease and construction method thereof
KR102513632B1 (en) * 2021-11-30 2023-03-28 주식회사 왓슨알앤디 Vaccine platform to produce foot-and-mouth disease virus-like particles
CN117304271B (en) * 2023-09-27 2024-04-16 中国农业科学院兰州兽医研究所 O-type foot-and-mouth disease virus VP2 protein T cell epitope polypeptide and application thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE4090351T1 (en) 1989-03-08 1997-07-24 Health Research Inc Recombinant smallpox virus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
ES2070997T3 (en) 1989-12-04 1995-06-16 Akzo Nobel Nv RECOMBINANT HERPES VIRUSES OF TURKEYS AND LIVING VECTOR VACCINES DERIVED FROM THEM.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
PT681483E (en) 1993-01-26 2005-11-30 Wyeth Corp COMPOSITIONS AND METHODS FOR DISTRIBUTION OF GENETIC MATERIAL
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (en) 1994-11-02 1996-06-03 Meyn Maschf Device for processing poultry suspended from its legs.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
DK1023107T3 (en) 1997-04-03 2006-12-27 Electrofect As Method of administration of pharmaceutical compositions and nucleic acids in skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
EP2428249B1 (en) 1998-07-13 2015-10-07 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
WO2000056916A2 (en) 1999-03-18 2000-09-28 Exiqon A/S Detection of mutations in genes by specific lna primers
JP3543326B2 (en) 2001-08-30 2004-07-14 ソニー株式会社 Information processing apparatus and method, information processing system, information distribution apparatus, recording medium, and program
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
WO2004085635A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Melan-a peptide analogue-virus-like-particle conjugates
EP2664672A1 (en) 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2004108260A2 (en) 2003-05-30 2004-12-16 Advisys, Inc. Devices and methods for biomaterial production
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CN1290579C (en) * 2003-10-15 2006-12-20 北京迪威华宇生物技术有限公司 Recombinant foot-and-mouth disease virus VP1 confluent protein vaccine
CN1275649C (en) * 2003-11-07 2006-09-20 复旦大学 Bivalence polypeptide vaccine for resisting A type and O type foot-and-mouth disease virus and its preparation
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
EP1773387B1 (en) * 2004-06-25 2013-06-12 Merial Ltd. Avipox recombinants expressing foot and mouth disease virus genes
CN1737144A (en) 2004-08-18 2006-02-22 金宁一 Composite multiple epitope bivalent nucleic acid vaccine construction for foot-and-mouth disease
EP2295590A1 (en) * 2004-09-03 2011-03-16 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP2808384B1 (en) * 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
WO2006063445A1 (en) 2004-12-14 2006-06-22 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Recombinant foot and mouth disease vaccine
CN101121938B (en) * 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 Method for preparing foot-and-mouth disease antigen
CN100572541C (en) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 Dual-purpose vaccine carrier for foot and mouth disease virus, its preparation method and application
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
CN101270155B (en) 2008-05-06 2011-04-27 中国农业科学院兰州兽医研究所 Method for assembling foot and mouth disease virus hollow capsid in insect with acidproof improvement
ES2344875B1 (en) * 2008-05-27 2011-06-29 Consejo Superior De Investigaciones Cientificas (Csic) (70%) VACCINE ATTENTIONED FOR FEVERY FEVER.

Also Published As

Publication number Publication date
JP2021121207A (en) 2021-08-26
CA2777705A1 (en) 2011-05-05
JP2015166353A (en) 2015-09-24
EP2498814A4 (en) 2013-11-13
AU2010313132A1 (en) 2012-05-17
US20220009971A1 (en) 2022-01-13
CA3177356A1 (en) 2011-05-05
WO2011054011A3 (en) 2011-08-04
JP2017131223A (en) 2017-08-03
CN102712931A (en) 2012-10-03
BR112012010357B1 (en) 2022-05-24
WO2011054011A4 (en) 2011-09-22
CA3030893C (en) 2022-11-29
MX2012004967A (en) 2012-11-21
KR20200092416A (en) 2020-08-03
JP7269987B2 (en) 2023-05-09
KR101965337B1 (en) 2019-04-03
US9109014B2 (en) 2015-08-18
CA3030893A1 (en) 2011-05-05
US11124545B2 (en) 2021-09-21
KR20180042464A (en) 2018-04-25
KR20120114217A (en) 2012-10-16
KR101851699B1 (en) 2018-04-24
EP2498814A2 (en) 2012-09-19
WO2011054011A2 (en) 2011-05-05
JP6085636B2 (en) 2017-02-22
JP2019213523A (en) 2019-12-19
US10294278B2 (en) 2019-05-21
JP2023100733A (en) 2023-07-19
CN106987595B (en) 2021-07-06
US20120282217A1 (en) 2012-11-08
AU2010313132B2 (en) 2015-01-15
US20200017553A1 (en) 2020-01-16
KR20190037367A (en) 2019-04-05
US20160039886A1 (en) 2016-02-11
BR112012010357A2 (en) 2017-10-03
KR102138780B1 (en) 2020-07-29
JP2013509203A (en) 2013-03-14
CA2777705C (en) 2019-03-12
KR20210149203A (en) 2021-12-08
EP2498814B1 (en) 2015-09-09
JP6545731B2 (en) 2019-07-17
CN106987595A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
IN2012DN03928A (en)
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2008014521A8 (en) Improved vaccines and methods for using the same
EA201891712A3 (en) NUCLEIC ACID MOLECULES OF INFLUENZA AND VACCINES PRODUCED FROM THEM
MX343830B (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same.
EP3552622A3 (en) Priming of an immune response
IL189313A0 (en) Virus-like particles as vaccines for paramyxovirus
WO2004080403A3 (en) Influenza virus vaccine
WO2008115199A3 (en) Chimeric virus vaccines
WO2010057159A3 (en) Antigens that elicit immune response against flavivirus and methods of using same
WO2016100328A8 (en) Novel tilapia virus and uses thereof
WO2013001285A3 (en) Fmdv vp1 peptides
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
EP4272833A3 (en) Hepatitis b virus (hbv) vaccines and uses thereof
EA202090759A3 (en) CORE PROTEIN OF HEPATITIS B VIRUS AND SURFACE ANTIGENIC PROTEIN AND THEIR VACCINE
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
WO2014145951A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
MX2022003590A (en) Vaccine in the form of a recombinant sero type 9 avian adenovirus vector.
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
WO2011038473A8 (en) Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of dna and chimeric virus vaccines
MX363149B (en) Influenza nucleoprotein vaccines.
BR112017024283A2 (en) dengue vaccines
EA201990539A1 (en) NEW PARAMYXOVIRUS AND ITS APPLICATION
WO2011041788A3 (en) Turkey viral hepatitis virus and uses thereof